title: [Chemoradiotherapy-chemotherapy for grade III inoperable non-small-cell lung cancer].
abstract: OBJECTIVE
  The purpose of this work was to assess results obtained with the MIP (mitomycin 6 mg/m(2) day 1, ifosfamide 1500 mg/m(2) days 1,2, 3, cisplatin 30 mg/m(2) days 1,2, 3) chemotherapy protocol combined with cisplatin-sensitized chest radiotherapy as developed in the French multicentric trial on perioperative chemotherapy.
  
  
  METHODS
  Thirty-five patients with grade III non-small-cell lung cancer (NSCLC) were given two or three starter MIP cycles every 4 weeks then underwent radiation therapy for six weeks for a total dose of 60 Gy with injection of 8 mg/m(2) cisplatin every day for the first two weeks and the last two weeks of treatment. In case of objective response (OR) to MIP before radiotherapy, the MIP protocol was repeated for one to four supplementary cycles according to tolerance.
  
  
  RESULTS
  The rate of OR after MIP was 51% and after chemoradiotherapy it was 69%. Toxic effects were limited to one death due to aplasia and 18 cases of grade 3-4 toxicity, mainly due to hematology disorders. Moderate esophagitis was observed in ten cases. Median survival was 13.5 months. Survival rates were 57% and 29% at one and two years.
  
  
  CONCLUSIONS
  This novel scheme, which can be improved, has demonstrated its efficacy. Tolerance is satisfactory and the cost is low compared with associations using "new" drugs.
authors.affiliation: Service de Pneumologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris VI, 75012 Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Lebeau
authors.forename: T
authors.initials: T
authors.lastname: Urban
authors.forename: M
authors.initials: M
authors.lastname: Baud
authors.forename: T
authors.initials: T
authors.lastname: Collon
authors.forename: Y
authors.initials: Y
authors.lastname: Le Guen
authors.forename: M
authors.initials: M
authors.lastname: Febvre
authors.forename: E
authors.initials: E
authors.lastname: Touboul
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D002945:Cisplatin; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D007069:Ifosfamide; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D015337:Multicenter Studies as Topic; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D016685:Mitomycin; D002945:Cisplatin; D007069:Ifosfamide